A carregar...

Phase II Randomized Study of Enzastaurin (LY317615) for Lung Cancer Prevention in Former Smokers

BACKGROUND: Chemoprevention for lung cancer with neutraceuticals or anti-inflammatory agents has had mixed clinical benefit. Novel targeted agents hold the promise of greater efficacy and selectivity. Here, we evaluated enzastaurin, a selective PKC-β inhibitor with antiproliferative and proapoptotic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gray, Jhanelle E., Altiok, Soner, Alexandrow, Mark G., Walsh, Frank W., Chen, Jian, Schell, Michael J., Tai, Datchen Fritz, Bepler, Gerold
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3578040/
https://ncbi.nlm.nih.gov/pubmed/23065656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.27836
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!